Mini Review - Asian Journal of Biomedical and Pharmaceutical Sciences (2020) Volume 10, Issue 72

Mini Review: Heparin treatment in COVID-19: Where are we?

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.

Author(s): Rizzo M, Pezone I, Amicone M, Riccio E, Pisani A*

Abstract PDF